Arca
Skip to content

Primary biliary cirrhosis

Drug research and approvals for primary biliary cirrhosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 36 studies of primary biliary cirrhosis are recruiting on ClinicalTrials.gov, Health Canada has authorized 7 drug trials for it since 2013, and FDA has 1 approved and 2 open orphan designations naming it.

  • Recruiting worldwide: 36
  • Trials authorized in Canada: 7
  • FDA orphan approvals: 1
  • EU medicines: 0

Recruiting Now

Newest start dates first, of 36 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

Newest first; search them all in Canada trials
Jun 27, 2017A double-blind, randomized, placebo-controlled clinical trial to assess the efficacy and safety of oral gkt137831 in patients with primary biliary cholangitis…GKT137831GENKYOTEX SAClosed
Feb 25, 2016A multi-part, randomized, double-blind, placebo-controlled study to assess the safety, tolerability and efficacy of ljn452 in patients with primary biliary…TROPIFEXOR (LJN452)Novartis Pharmaceuticals CorporationOngoing
Sep 16, 2015A 12-week, double-blind, randomized, placebo-controlled, phase 2 study, to evaluate the effects of two doses of mbx-8025 in subjects with primary biliary…MBX-8025CYMABAY THERAPEUTICS INCOngoing
Jul 21, 2015A phase 3b, double blind, randomized, placebo controlled, multicenter study evaluating the effect of obeticholic acid on clinical outcomes in subjects with…OBETICHOLIC ACID (INT-747)AlfasigmaClosed
Feb 10, 2015An open-label, multicenter extension study to evaluate the long-term safety and tolerability of lum001, an apical sodium-dependent bile acid transporter…LUM001LUMENA PHARMACEUTICALS INCClosed
Jul 3, 2014A phase 2, randomized, double-blind, placebo-controlled study to evaluate lum001, an apical sodium-dependent bile acid transporter inhibitor (asbti), in…MARALIXIBAT (LUM001)LUMENA PHARMACEUTICALS INCClosed
Jun 21, 2013Pilot study of tenofovir and emtricitabine for primary biliary cirrhosisEMTRICITABINE/TENOFOVIRGOVERNORS OF THE UNIVERSITY OF ALBERTAPending

FDA Orphan Designations

Approved first, then open designations, newest first
Dec 10, 1997URSO 250Treatment of patients with primary biliary cirrhosisAptalis Pharma US, Inc.Approved
Oct 31, 2012(2S)-2-{[(2R)-2-[({[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5…Treatment of primary biliary cirrhosisIpsen Biopharmaceuticals, Inc.Designated
Feb 19, 1991UrsodiolManagement of the clinical signs and symptoms associated with primary biliary cirrhosis.Novartis Pharmaceuticals CorporationDesignated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.